Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

NCT04044937 is registered in ClinicalTrials.gov with Thomas Hope as lead sponsor.

NCT NCT04044937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04044937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
Lead sponsor
Thomas Hope
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2018
Completion date
March 31, 2024
Enrollment
143 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intracranial neoplasm, low grade glioma, recurrent glioblastoma, recurrent who grade iii glioma, recurrent world health organization (who) grade ii glioma